

# Adrian V S Hill

## List of Articles by Year in descending order

Source: [//exaly.com/author-pdf/7612716/publications.pdf](https://exaly.com/author-pdf/7612716/publications.pdf)

Version: 2025-02-01

330

PR articles

35,212

PR citations

2854

89

PR h-index

3060

184

g-index

348

documents

40760

doc citations

2897

96

h-index

56565

citing authors

#	ARTICLE	IF	CITATIONS
1	Altered IL-6 signalling and risk of tuberculosis: a multi-ancestry mendelian randomisation study. <i>Lancet Microbe</i> , The, 2025, 6, 100922.	12.3	20
2	R21 in Matrix-M adjuvant in UK malaria-naïve adult men and non-pregnant women aged 18–45 years: an open-label, partially blinded, phase 1a controlled human malaria infection study. <i>Lancet Microbe</i> , The, 2025, 6, 100867.	12.3	7
3	A phase 1/2a clinical trial to assess safety and immunogenicity of an adenoviral-vectored capsular group B meningococcal vaccine. <i>Science Translational Medicine</i> , 2025, 17, .	12.5	2
4	Core-shell microcapsules compatible with routine injection enable prime/boost immunization against malaria with a single shot. <i>Science Translational Medicine</i> , 2025, 17, .	12.5	0
5	Repertoire, function, and structure of serological antibodies induced by the R21/Matrix-M malaria vaccine. <i>Journal of Experimental Medicine</i> , 2025, 222, .	9.2	4
6	A common NFKB1 variant detected through antibody analysis in UK Biobank predicts risk of infection and allergy. <i>American Journal of Human Genetics</i> , 2024, 111, 295-308.	6.5	2
7	High-resolution African HLA resource uncovers HLA-DRB1 expression effects underlying vaccine response. <i>Nature Medicine</i> , 2024, 30, 1384-1394.	33.0	11
8	A randomised trial of malaria vaccine R21/Matrix-M, with and without antimalarial drugs in Thai adults. <i>Npj Vaccines</i> , 2024, 9, .	5.3	6
9	A comparative immunological assessment of multiple clinical-stage adjuvants for the R21 malaria vaccine in nonhuman primates. <i>Science Translational Medicine</i> , 2024, 16, .	12.5	7
10	An adenoviral-vectored vaccine confers seroprotection against capsular group B meningococcal disease. <i>Science Translational Medicine</i> , 2023, 15, .	12.5	5
11	Mexican Biobank advances population and medical genomics of diverse ancestries. <i>Nature</i> , 2023, 622, 775-783.	37.9	109
12	A single-shot adenoviral vaccine provides hemagglutinin stalk-mediated protection against heterosubtypic influenza challenge in mice. <i>Molecular Therapy</i> , 2022, 30, 2024-2047.	10.2	34
13	Imputation Performance in Latin American Populations: Improving Rare Variants Representation With the Inclusion of Native American Genomes. <i>Frontiers in Genetics</i> , 2022, 12, .	2.3	13
14	Deep Immune Phenotyping and Single-Cell Transcriptomics Allow Identification of Circulating TRM-Like Cells Which Correlate With Liver-Stage Immunity and Vaccine-Induced Protection From Malaria. <i>Frontiers in Immunology</i> , 2022, 13, .	4.9	16
15	CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination. <i>JCI Insight</i> , 2022, 7, .	5.4	11
16	Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV. <i>JCI Insight</i> , 2022, 7, .	5.4	37
17	Identification of host-pathogen-disease relationships using a scalable multiplex serology platform in UK Biobank. <i>Nature Communications</i> , 2022, 13, .	13.7	67
18	A loss-of-function IFNAR1 allele in Polynesia underlies severe viral diseases in homozygotes. <i>Journal of Experimental Medicine</i> , 2022, 219, .	9.2	59

#	ARTICLE	IF	CITATIONS
19	Production of a high purity, C�tagged hepatitis B surface antigen fusion protein VLP vaccine for malaria expressed in <i>Pichia pastoris</i> under cGMP conditions. <i>Biotechnology and Bioengineering</i> , 2022, 119, 2784-2793.	3.9	6
20	Ancient DNA reveals five streams of migration into Micronesia and matrilocality in early Pacific seafarers. <i>Science</i> , 2022, 377, 72-79.	36.2	30
21	Genome-wide association study of leprosy in Malawi and Mali. <i>PLoS Pathogens</i> , 2022, 18, e1010312.	4.4	4
22	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. <i>Lancet, The</i> , 2021, 397, 99-111.	62.3	4,401
23	Malaria is a cause of iron deficiency in African children. <i>Nature Medicine</i> , 2021, 27, 653-658.	33.0	54
24	Low immunogenicity of malaria pre�erythrocytic stages can be overcome by vaccination. <i>EMBO Molecular Medicine</i> , 2021, 13, .	7.1	12
25	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. <i>Lancet, The</i> , 2021, 397, 881-891.	62.3	1,097
26	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. <i>Lancet, The</i> , 2021, 397, 1351-1362.	62.3	592
27	Ultra-low dose immunization and multi-component vaccination strategies enhance protection against malaria in mice. <i>Scientific Reports</i> , 2021, 11, .	3.4	19
28	Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial. <i>Lancet, The</i> , 2021, 397, 1809-1818.	62.3	399
29	Dissection-independent production of <i>Plasmodium</i> sporozoites from whole mosquitoes. <i>Life Science Alliance</i> , 2021, 4, e202101094.	2.6	7
30	A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial. <i>Nature Communications</i> , 2021, 12, .	13.7	56
31	Screening of viral-vectored <i>P. falciparum</i> pre-erythrocytic candidate vaccine antigens using chimeric rodent parasites. <i>PLoS ONE</i> , 2021, 16, e0254498.	2.3	2
32	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. <i>Lancet HIV, the</i> , 2021, 8, e474-e485.	7.9	230
33	A three-antigen <i>Plasmodium falciparum</i> DNA prime�Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-na�ve adults. <i>PLoS ONE</i> , 2021, 16, e0256980.	2.3	17
34	Poor CD4+ T Cell Immunogenicity Limits Humoral Immunity to <i>P. falciparum</i> Transmission-Blocking Candidate Pfs25 in Humans. <i>Frontiers in Immunology</i> , 2021, 12, .	4.9	9
35	Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. <i>Nature Medicine</i> , 2021, 27, 2032-2040.	33.0	1,113
36	Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy. , 2021, 9, e003218.		23

#	ARTICLE	IF	CITATIONS
37	Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). <i>Lancet, The</i> , 2021, 398, 981-990.	62.3	247
38	Paths and timings of the peopling of Polynesia inferred from genomic networks. <i>Nature</i> , 2021, 597, 522-526.	37.9	58
39	Characterisation of factors contributing to the performance of nonwoven fibrous matrices as substrates for adenovirus vectored vaccine stabilisation. <i>Scientific Reports</i> , 2021, 11, .	3.4	4
40	Identification of antigens presented by MHC for vaccines against tuberculosis. <i>Npj Vaccines</i> , 2020, 5, .	5.3	101
41	Targeting Antigen to the Surface of EVs Improves the InÂVivo Immunogenicity of Human and Non-human Adenoviral Vaccines in Mice. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 16, 108-125.	4.1	48
42	Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. <i>Lancet, The</i> , 2020, 396, 467-478.	62.3	2,309
43	Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. <i>Lancet, The</i> , 2020, 396, 1979-1993.	62.3	1,338
44	The Human Leukocyte Antigen Locus and Rheumatic Heart Disease Susceptibility in South Asians and Europeans. <i>Scientific Reports</i> , 2020, 10, .	3.4	14
45	Risk of pneumococcal bacteremia in Kenyan children with glucose-6-phosphate dehydrogenase deficiency. <i>BMC Medicine</i> , 2020, 18, .	7.1	7
46	Generation of Novel Plasmodium falciparum NF135 and NF54 Lines Expressing Fluorescent Reporter Proteins Under the Control of Strong and Constitutive Promoters. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, .	4.1	18
47	Estimating the burden of iron deficiency among African children. <i>BMC Medicine</i> , 2020, 18, .	7.1	64
48	Native American gene flow into Polynesia predating Easter Island settlement. <i>Nature</i> , 2020, 583, 572-577.	37.9	98
49	Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial. , 2020, 8, e000928.		35
50	Preclinical Development and Assessment of Viral Vectors Expressing a Fusion Antigen of Plasmodium falciparum LSA1 and LSAP2 for Efficacy against Liver-Stage Malaria. <i>Infection and Immunity</i> , 2020, 88, .	2.7	9
51	Modification of Adenovirus vaccine vector-induced immune responses by expression of a signalling molecule. <i>Scientific Reports</i> , 2020, 10, .	3.4	12
52	Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. <i>Lancet Infectious Diseases, The</i> , 2020, 20, 816-826.	16.5	218
53	Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. <i>Nature Medicine</i> , 2020, 27, 279-288.	33.0	306
54	T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. <i>Nature Medicine</i> , 2020, 27, 270-278.	33.0	548

#	ARTICLE	IF	CITATIONS
55	TMEM203 is a binding partner and regulator of STING-mediated inflammatory signaling in macrophages. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 16479-16488.	7.5	54
56	Safety and efficacy of ChAdOx1 RVF vaccine against Rift Valley fever in pregnant sheep and goats. Npj Vaccines, 2019, 4, .	5.3	37
57	The ferroportin Q248H mutation protects from anemia, but not malaria or bacteremia. Science Advances, 2019, 5, .	10.9	26
58	Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal. Journal of Infectious Diseases, 2019, 219, 1187-1197.	3.8	78
59	Common Genetic Variations Associated with the Persistence of Immunity following Childhood Immunization. Cell Reports, 2019, 27, 3241-3253.e4.	6.3	29
60	A P. falciparum NF54 Reporter Line Expressing mCherry-Luciferase in Gametocytes, Sporozoites, and Liver-Stages. Frontiers in Cellular and Infection Microbiology, 2019, 9, .	4.1	33
61	Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine. Vaccines, 2019, 7, 40.	2.9	24
62	Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell Line. Vaccines, 2019, 7, 33.	2.9	25
63	Use of gene expression studies to investigate the human immunological response to malaria infection. Malaria Journal, 2019, 18, .	2.6	14
64	Iron Status and Associated Malaria Risk Among African Children. Clinical Infectious Diseases, 2019, 68, 1807-1814.	5.2	46
65	Validation of Multiplex Serology for human hepatitis viruses B and C, human T-lymphotropic virus 1 and Toxoplasma gondii. PLoS ONE, 2019, 14, e0210407.	2.3	22
66	Elevated risk of invasive group A streptococcal disease and host genetic variation in the human leucocyte antigen locus. Genes and Immunity, 2019, 21, 63-70.	3.8	7
67	Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP. Scientific Reports, 2018, 8, .	3.4	41
68	Language continuity despite population replacement in Remote Oceania. Nature Ecology and Evolution, 2018, 2, 731-740.	9.6	116
69	Genetic variation in VAC14 is associated with bacteremia secondary to diverse pathogens in African children. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, .	7.5	13
70	Risk of nontyphoidal Salmonella bacteraemia in African children is modified by STAT4. Nature Communications, 2018, 9, .	13.7	31
71	DOPS Adjuvant Confers Enhanced Protection against Malaria for VLP-TRAP Based Vaccines. Diseases (Basel, Switzerland), 2018, 6, 107.	2.7	9
72	First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children. PLoS ONE, 2018, 13, e0208328.	2.3	63

#	ARTICLE	IF	CITATIONS
73	CXCR3+ T Follicular Helper Cells Induced by Co-Administration of RTS,S/AS01B and Viral-Vectored Vaccines Are Associated With Reduced Immunogenicity and Efficacy Against Malaria. <i>Frontiers in Immunology</i> , 2018, 9, .	4.9	43
74	Prime and target immunization protects against liver-stage malaria in mice. <i>Science Translational Medicine</i> , 2018, 10, .	12.5	79
75	Development of a Molecular Adjuvant to Enhance Antigen-Specific CD8+ T Cell Responses. <i>Scientific Reports</i> , 2018, 8, .	3.4	22
76	A simian-adenovirus-vectored rabies vaccine suitable for thermostabilisation and clinical development for low-cost single-dose pre-exposure prophylaxis. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006870.	3.0	48
77	Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP. <i>Npj Vaccines</i> , 2018, 3, .	5.3	56
78	Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors. <i>Nature Communications</i> , 2018, 9, .	13.7	83
79	Activation-induced Markers Detect Vaccine-Specific CD4+ T Cell Responses Not Measured by Assays Conventionally Used in Clinical Trials. <i>Vaccines</i> , 2018, 6, 50.	2.9	79
80	Qualified Biolayer Interferometry Avidity Measurements Distinguish the Heterogeneity of Antibody Interactions with <i>Plasmodium falciparum</i> Circumsporozoite Protein Antigens. <i>Journal of Immunology</i> , 2018, 201, 1315-1326.	0.6	40
81	Tailoring a <i>Plasmodium vivax</i> Vaccine To Enhance Efficacy through a Combination of a CSP Virus-Like Particle and TRAP Viral Vectors. <i>Infection and Immunity</i> , 2018, 86, .	2.7	41
82	Adenovirus-prime and baculovirus-boost heterologous immunization achieves sterile protection against malaria sporozoite challenge in a murine model. <i>Scientific Reports</i> , 2018, 8, .	3.4	19
83	Evaluation of <i>Plasmodium vivax</i> Cell-Traversal Protein for Ookinetes and Sporozoites as a Preerythrocytic <i>P. vivax</i> Vaccine. <i>Vaccine Journal</i> , 2017, 24, .	3.1	23
84	Human genetic and metabolite variation reveals that methylthioadenosine is a prognostic biomarker and an inflammatory regulator in sepsis. <i>Science Advances</i> , 2017, 3, .	10.9	52
85	Viral Vector Malaria Vaccines Induce High-Level T Cell and Antibody Responses in West African Children and Infants. <i>Molecular Therapy</i> , 2017, 25, 547-559.	10.2	43
86	Rational development of a protective <i>P. vivax</i> vaccine evaluated with transgenic rodent parasite challenge models. <i>Scientific Reports</i> , 2017, 7, .	3.4	51
87	Association between a common immunoglobulin heavy chain allele and rheumatic heart disease risk in Oceania. <i>Nature Communications</i> , 2017, 8, .	13.7	137
88	Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine. <i>Scientific Reports</i> , 2017, 7, .	3.4	235
89	ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice. <i>Vaccine</i> , 2017, 35, 3780-3788.	3.1	152
90	Cryopreservation-related loss of antigen-specific IFN $\gamma$ producing CD4+ T-cells can skew immunogenicity data in vaccine trials: Lessons from a malaria vaccine trial substudy. <i>Vaccine</i> , 2017, 35, 1898-1906.	3.1	46

#	ARTICLE	IF	CITATIONS
91	Shared and Distinct Aspects of the Sepsis Transcriptomic Response to Fecal Peritonitis and Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 328-339.	8.9	234
92	Chimpanzee adenoviral vectors as vaccines for outbreak pathogens. Human Vaccines and Immunotherapeutics, 2017, 13, 3020-3032.	3.1	80
93	Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-M <sub>1</sub> . Vaccine, 2017, 35, 6208-6217.	3.1	34
94	Adjuvanting a viral vectored vaccine against pre-erythrocytic malaria. Scientific Reports, 2017, 7, .	3.4	16
95	An in vitro assay to measure antibody-mediated inhibition of P. berghei sporozoite invasion against P. falciparum antigens. Scientific Reports, 2017, 7, .	3.4	21
96	Safety and Immunogenicity of Malaria Vectored Vaccines Given with Routine Expanded Program on Immunization Vaccines in Gambian Infants and Neonates: A Randomized Controlled Trial. Frontiers in Immunology, 2017, 8, .	4.9	26
97	Human vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies. JCI Insight, 2017, 2, .	5.4	96
98	Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions. JCI Insight, 2017, 2, .	5.4	136
99	Highly-Immunogenic Virally-Vectored T-cell Vaccines Cannot Overcome Subversion of the T-cell Response by HCV during Chronic Infection. Vaccines, 2016, 4, 27.	2.9	38
100	Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal. PLoS ONE, 2016, 11, e0167951.	2.3	50
101	Potency of a thermostabilised chimpanzee adenovirus Rift Valley Fever vaccine in cattle. Vaccine, 2016, 34, 2296-2298.	3.1	33
102	Genetic Factors of the Disease Course after Sepsis: A Genome-Wide Study for 28 Day Mortality. EBioMedicine, 2016, 12, 239-246.	9.7	62
103	Chimpanzee Adenovirus Vaccine Provides Multispecies Protection against Rift Valley Fever. Scientific Reports, 2016, 6, .	3.4	110
104	Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants. Molecular Therapy, 2016, 24, 1470-1477.	10.2	63
105	Viral vectors as vaccine platforms: from immunogenicity to impact. Current Opinion in Immunology, 2016, 41, 47-54.	5.2	168
106	Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP. Journal of Infectious Diseases, 2016, 214, 772-781.	3.8	108
107	Polymorphism in a lincRNA Associates with a Doubled Risk of Pneumococcal Bacteremia in Kenyan Children. American Journal of Human Genetics, 2016, 98, 1092-1100.	6.5	44
108	A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. New England Journal of Medicine, 2016, 374, 1635-1646.	34.6	322

#	ARTICLE	IF	CITATIONS
109	Enhancing cellular immunogenicity of MVA-vectored vaccines by utilizing the F11L endogenous promoter. <i>Vaccine</i> , 2016, 34, 49-55.	3.1	15
110	Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 31-42.	16.5	207
111	Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study. <i>Lancet Respiratory Medicine</i> , the, 2016, 4, 259-271.	23.4	741
112	Differential immunogenicity between HAdV-5 and chimpanzee adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop sequences in mice. <i>Scientific Reports</i> , 2015, 5, .	3.4	40
113	Distinct Transcriptional and Anti-Mycobacterial Profiles of Peripheral Blood Monocytes Dependent on the Ratio of Monocytes: Lymphocytes. <i>EBioMedicine</i> , 2015, 2, 1619-1626.	9.7	64
114	Malaria vaccines: identifying Plasmodium falciparum liver-stage targets. <i>Frontiers in Microbiology</i> , 2015, 6, .	3.9	24
115	Rare Variants in MYD88, IRAK4 and IKBKG and Susceptibility to Invasive Pneumococcal Disease: A Population-Based Case-Control Study. <i>PLoS ONE</i> , 2015, 10, e0123532.	2.3	8
116	Identification of Immunodominant Responses to the Plasmodium falciparum Antigens PflUIS3, PflSA1 and PflSAP2 in Multiple Strains of Mice. <i>PLoS ONE</i> , 2015, 10, e0144515.	2.3	5
117	Evaluation of the Efficacy of ChAd63-MVA Vectored Vaccines Expressing Circumsporozoite Protein and ME-TRAP Against Controlled Human Malaria Infection in Malaria-Naive Individuals. <i>Journal of Infectious Diseases</i> , 2015, 211, 1076-1086.	3.8	126
118	Variants in the Mannose-binding Lectin Gene MBL2 do not Associate With Sepsis Susceptibility or Survival in a Large European Cohort. <i>Clinical Infectious Diseases</i> , 2015, 61, 695-703.	5.2	25
119	Modeling Combinations of Pre-erythrocytic Plasmodium falciparum Malaria Vaccines. <i>American Journal of Tropical Medicine and Hygiene</i> , 2015, 93, 1254-1259.	0.0	6
120	Genome-wide association study of survival from sepsis due to pneumonia: an observational cohort study. <i>Lancet Respiratory Medicine</i> , the, 2015, 3, 53-60.	23.4	189
121	The relative magnitude of transgene-specific adaptive immune responses induced by human and chimpanzee adenovirus vectors differs between laboratory animals and a target species. <i>Vaccine</i> , 2015, 33, 1121-1128.	3.1	24
122	Genomic modulators of gene expression in human neutrophils. <i>Nature Communications</i> , 2015, 6, .	13.7	135
123	Comparative assessment of vaccine vectors encoding ten malaria antigens identifies two protective liver-stage candidates. <i>Scientific Reports</i> , 2015, 5, .	3.4	52
124	Genetic susceptibility to invasive Salmonella disease. <i>Nature Reviews Immunology</i> , 2015, 15, 452-463.	53.8	88
125	Increased sample volume and use of quantitative reverse-transcription PCR can improve prediction of liver-to-blood inoculum size in controlled human malaria infection studies. <i>Malaria Journal</i> , 2015, 14, .	2.6	43
126	Searching for the human genetic factors standing in the way of universally effective vaccines. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2015, 370, 20140341.	3.7	42

#	ARTICLE	IF	CITATIONS
127	Induction of CD8+ T cell responses and protective efficacy following microneedle-mediated delivery of a live adenovirus-vectored malaria vaccine. <i>Vaccine</i> , 2015, 33, 3248-3255.	3.1	32
128	Profiling the host response to malaria vaccination and malaria challenge. <i>Vaccine</i> , 2015, 33, 5316-5320.	3.1	21
129	Progress with viral vectored malaria vaccines: A multi-stage approach involving 'unnatural immunity'. <i>Vaccine</i> , 2015, 33, 7444-7451.	3.1	58
130	Development of an In Vitro Assay and Demonstration of Plasmodium berghei Liver-Stage Inhibition by TRAP-Specific CD8+ T Cells. <i>PLoS ONE</i> , 2015, 10, e0119880.	2.3	18
131	Enhanced Vaccine-Induced CD8+ T Cell Responses to Malaria Antigen ME-TRAP by Fusion to MHC Class II Invariant Chain. <i>PLoS ONE</i> , 2014, 9, e100538.	2.3	35
132	4-1BBL Enhances CD8+ T Cell Responses Induced by Vectored Vaccines in Mice but Fails to Improve Immunogenicity in Rhesus Macaques. <i>PLoS ONE</i> , 2014, 9, e105520.	2.3	7
133	A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. <i>Science Translational Medicine</i> , 2014, 6, .	12.5	325
134	Clinical Assessment of a Novel Recombinant Simian Adenovirus ChAdOx1 as a Vectored Vaccine Expressing Conserved Influenza A Antigens. <i>Molecular Therapy</i> , 2014, 22, 668-674.	10.2	186
135	Vaccine-elicited Human T Cells Recognizing Conserved Protein Regions Inhibit HIV-1. <i>Molecular Therapy</i> , 2014, 22, 464-475.	10.2	198
136	Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injection. <i>Frontiers in Microbiology</i> , 2014, 5, .	3.9	100
137	Efficacy of a Plasmodium vivax Malaria Vaccine Using ChAd63 and Modified Vaccinia Ankara Expressing Thrombospondin-Related Anonymous Protein as Assessed with Transgenic Plasmodium berghei Parasites. <i>Infection and Immunity</i> , 2014, 82, 1277-1286.	2.7	56
138	RNA and Imidazoquinolines Are Sensed by Distinct TLR7/8 Ectodomain Sites Resulting in Functionally Disparate Signaling Events. <i>Journal of Immunology</i> , 2014, 192, 5963-5973.	0.6	43
139	Analysis of human B cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection. <i>Immunology</i> , 2014, 141, 628-644.	4.7	44
140	IFITM3 and Susceptibility to Respiratory Viral Infections in the Community. <i>Journal of Infectious Diseases</i> , 2014, 209, 1028-1031.	3.8	74
141	Ratio of Monocytes to Lymphocytes in Peripheral Blood Identifies Adults at Risk of Incident Tuberculosis Among HIV-Infected Adults Initiating Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2014, 209, 500-509.	3.8	111
142	Exonic single nucleotide polymorphisms within TLR3 associated with infant responses to serogroup C meningococcal conjugate vaccine. <i>Vaccine</i> , 2014, 32, 3424-3430.	3.1	4
143	Coadministration of Seasonal Influenza Vaccine and MVA-NP+M1 Simultaneously Achieves Potent Humoral and Cell-Mediated Responses. <i>Molecular Therapy</i> , 2014, 22, 233-238.	10.2	104
144	Combining Viral Vectored and Protein-in-adjuvant Vaccines Against the Blood-stage Malaria Antigen AMA1: Report on a Phase 1a Clinical Trial. <i>Molecular Therapy</i> , 2014, 22, 2142-2154.	10.2	68

#	ARTICLE	IF	CITATIONS
145	Translating the Immunogenicity of Prime-boost Immunization With ChAd63 and MVA ME-TRAP From Malaria Naive to Malaria-endemic Populations. <i>Molecular Therapy</i> , 2014, 22, 1992-2003.	10.2	54
146	Microneedle-mediated immunization of an adenovirus-based malaria vaccine enhances antigen-specific antibody immunity and reduces anti-vector responses compared to the intradermal route. <i>Scientific Reports</i> , 2014, 4, .	3.4	52
147	External Quality Assurance of Malaria Nucleic Acid Testing for Clinical Trials and Eradication Surveillance. <i>PLoS ONE</i> , 2014, 9, e97398.	2.3	30
148	Assessment of Humoral Immune Responses to Blood-Stage Malaria Antigens following ChAd63-MVA Immunization, Controlled Human Malaria Infection and Natural Exposure. <i>PLoS ONE</i> , 2014, 9, e107903.	2.3	68
149	A Phase Ia Study to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 CS Administered Alone and with MVA CS. <i>PLoS ONE</i> , 2014, 9, e115161.	2.3	50
150	Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. <i>Nature Communications</i> , 2013, 4, .	13.7	272
151	Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley Fever vaccine in mice. <i>Virology Journal</i> , 2013, 10, .	3.6	55
152	Identifying Recent Adaptations in Large-Scale Genomic Data. <i>Cell</i> , 2013, 152, 703-713.	33.7	346
153	Identification of Targets of CD8+ T Cell Responses to Malaria Liver Stages by Genome-wide Epitope Profiling. <i>PLoS Pathogens</i> , 2013, 9, e1003303.	4.4	77
154	Determining the validity of hospital laboratory reference intervals for healthy young adults participating in early clinical trials of candidate vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 1741-1751.	3.1	6
155	Comparison of Modeling Methods to Determine Liver-to-blood Inocula and Parasite Multiplication Rates During Controlled Human Malaria Infection. <i>Journal of Infectious Diseases</i> , 2013, 208, 340-345.	3.8	57
156	Assessment of Immune Interference, Antagonism, and Diversion following Human Immunization with Biallelic Blood-Stage Malaria Viral-Vectored Vaccines and Controlled Malaria Infection. <i>Journal of Immunology</i> , 2013, 190, 1135-1147.	0.6	23
157	The utility of <i>Plasmodium berghei</i> as a rodent model for anti-merozoite malaria vaccine assessment. <i>Scientific Reports</i> , 2013, 3, .	3.4	37
158	Optimising Controlled Human Malaria Infection Studies Using Cryopreserved <i>P. falciparum</i> Parasites Administered by Needle and Syringe. <i>PLoS ONE</i> , 2013, 8, e65960.	2.3	84
159	Dry-Coated Live Viral Vector Vaccines Delivered by Nanopatch Microprojections Retain Long-Term Thermostability and Induce Transgene-Specific T Cell Responses in Mice. <i>PLoS ONE</i> , 2013, 8, e67888.	2.3	68
160	Safety and Immunogenicity of Heterologous Prime-Boost Immunisation with <i>Plasmodium falciparum</i> Malaria Candidate Vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in Healthy Gambian and Kenyan Adults. <i>PLoS ONE</i> , 2013, 8, e57726.	2.3	68
161	Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector. <i>Journal of Infectious Diseases</i> , 2012, 205, 772-781.	3.8	206
162	Single Nucleotide Polymorphisms in the Toll-Like Receptor 3 and CD44 Genes Are Associated with Persistence of Vaccine-Induced Immunity to the Serogroup C Meningococcal Conjugate Vaccine. <i>Vaccine Journal</i> , 2012, 19, 295-303.	3.1	18

#	ARTICLE	IF	CITATIONS
163	Vaccine Vectors Derived from a Large Collection of Simian Adenoviruses Induce Potent Cellular Immunity Across Multiple Species. <i>Science Translational Medicine</i> , 2012, 4, .	12.5	281
164	Preliminary Assessment of the Efficacy of a T-Cell-Based Influenza Vaccine, MVA-NP+M1, in Humans. <i>Clinical Infectious Diseases</i> , 2012, 55, 19-25.	5.2	231
165	Bayesian refinement of association signals for 14 loci in 3 common diseases. <i>Nature Genetics</i> , 2012, 44, 1294-1301.	25.2	523
166	ChAd63-MVA- vectored Blood-stage Malaria Vaccines Targeting MSP1 and AMA1: Assessment of Efficacy Against Mosquito Bite Challenge in Humans. <i>Molecular Therapy</i> , 2012, 20, 2355-2368.	10.2	210
167	Distinguishing malaria and influenza: Early clinical features in controlled human experimental infection studies. <i>Travel Medicine and Infectious Disease</i> , 2012, 10, 192-196.	2.5	11
168	Common variants at 11p13 are associated with susceptibility to tuberculosis. <i>Nature Genetics</i> , 2012, 44, 257-259.	25.2	211
169	Evolution, revolution and heresy in the genetics of infectious disease susceptibility. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2012, 367, 840-849.	3.7	122
170	Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy?. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 706-714.	3.1	79
171	Mixed Vector Immunization With Recombinant Adenovirus and MVA Can Improve Vaccine Efficacy While Decreasing Antivector Immunity. <i>Molecular Therapy</i> , 2012, 20, 1633-1647.	10.2	41
172	Fusion of the Mycobacterium tuberculosis Antigen 85A to an Oligomerization Domain Enhances Its Immunogenicity in Both Mice and Non-Human Primates. <i>PLoS ONE</i> , 2012, 7, e33555.	2.3	46
173	Identification of 34 Novel Proinflammatory Proteins in a Genome-Wide Macrophage Functional Screen. <i>PLoS ONE</i> , 2012, 7, e42388.	2.3	10
174	T Cell Responses Induced by Adenoviral Vectored Vaccines Can Be Adjuvanted by Fusion of Antigen to the Oligomerization Domain of C4b-Binding Protein. <i>PLoS ONE</i> , 2012, 7, e44943.	2.3	23
175	A T Cell-Inducing Influenza Vaccine for the Elderly: Safety and Immunogenicity of MVA-NP+M1 in Adults Aged over 50 Years. <i>PLoS ONE</i> , 2012, 7, e48322.	2.3	117
176	Novel Adenovirus-Based Vaccines Induce Broad and Sustained T Cell Responses to HCV in Man. <i>Science Translational Medicine</i> , 2012, 4, .	12.5	378
177	Human genetic susceptibility to infectious disease. <i>Nature Reviews Genetics</i> , 2012, 13, 175-188.	47.0	449
178	Coated microneedle arrays for transcutaneous delivery of live virus vaccines. <i>Journal of Controlled Release</i> , 2012, 159, 34-42.	11.0	160
179	Preventing spontaneous genetic rearrangements in the transgene cassettes of adenovirus vectors. <i>Biotechnology and Bioengineering</i> , 2012, 109, 719-728.	3.9	50
180	Phase Ia Clinical Evaluation of the Safety and Immunogenicity of the Plasmodium falciparum Blood-Stage Antigen AMA1 in ChAd63 and MVA Vaccine Vectors. <i>PLoS ONE</i> , 2012, 7, e31208.	2.3	164

#	ARTICLE	IF	CITATIONS
181	Comparison of Clinical and Parasitological Data from Controlled Human Malaria Infection Trials. PLoS ONE, 2012, 7, e38434.	2.3	69
182	A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence: Improved Systems for Vector Derivation and Comparative Immunogenicity. PLoS ONE, 2012, 7, e40385.	2.3	354
183	Optimising Immunogenicity with Viral Vectors: Mixing MVA and HAdV-5 Expressing the Mycobacterial Antigen Ag85A in a Single Injection. PLoS ONE, 2012, 7, e50447.	2.3	27
184	The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody. Nature Communications, 2011, 2, .	13.7	264
185	A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine. Vaccine, 2011, 29, 7514-7522.	3.1	48
186	Transgene Optimization, Immunogenicity and In Vitro Efficacy of Viral Vectored Vaccines Expressing Two Alleles of Plasmodium falciparum AMA1. PLoS ONE, 2011, 6, e20977.	2.3	47
187	Microneedle Array Design Determines the Induction of Protective Memory CD8+ T Cell Responses Induced by a Recombinant Live Malaria Vaccine in Mice. PLoS ONE, 2011, 6, e22442.	2.3	72
188	Human genetic susceptibility to intracellular pathogens. Immunological Reviews, 2011, 240, 105-116.	6.5	105
189	Viral vectors as vaccine platforms: deployment in sight. Current Opinion in Immunology, 2011, 23, 377-382.	5.2	197
190	Vaccines and global health. Philosophical Transactions of the Royal Society B: Biological Sciences, 2011, 366, 2733-2742.	3.7	31
191	Phase Ia Clinical Evaluation of the Plasmodium falciparum Blood-stage Antigen MSP1 in ChAd63 and MVA Vaccine Vectors. Molecular Therapy, 2011, 19, 2269-2276.	10.2	161
192	Potent CD8+ T-Cell Immunogenicity in Humans of a Novel Heterosubtypic Influenza A Vaccine, MVA-NP+M1. Clinical Infectious Diseases, 2011, 52, 1-7.	5.2	434
193	Vaccines against malaria. Philosophical Transactions of the Royal Society B: Biological Sciences, 2011, 366, 2806-2814.	3.7	175
194	Two Human MYD88 Variants, S34Y and R98C, Interfere with MyD88-IRAK4-Myddosome Assembly. Journal of Biological Chemistry, 2011, 286, 1341-1353.	2.2	72
195	The Requirement for Potent Adjuvants To Enhance the Immunogenicity and Protective Efficacy of Protein Vaccines Can Be Overcome by Prior Immunization with a Recombinant Adenovirus. Journal of Immunology, 2011, 187, 2602-2616.	0.6	56
196	Partially Randomized, Non-Blinded Trial of DNA and MVA Therapeutic Vaccines Based on Hepatitis B Virus Surface Protein for Chronic HBV Infection. PLoS ONE, 2011, 6, e14626.	2.3	65
197	Impact on Malaria Parasite Multiplication Rates in Infected Volunteers of the Protein-in-Adjuvant Vaccine AMA1-C1/Alhydrogel+CPG 7909. PLoS ONE, 2011, 6, e22271.	2.3	88
198	Long-Term Thermostabilization of Live Poxviral and Adenoviral Vaccine Vectors at Supraphysiological Temperatures in Carbohydrate Glass. Science Translational Medicine, 2010, 2, .	12.5	150

#	ARTICLE	IF	CITATIONS
199	Genome-wide association analyses identifies a susceptibility locus for tuberculosis on chromosome 18q11.2. <i>Nature Genetics</i> , 2010, 42, 739-741.	25.2	353
200	Prime-boost vectored malaria vaccines: Progress and prospects. <i>Hum Vaccin</i> , 2010, 6, 78-83.	2.8	188
201	A Naturally Occurring Variant in Human TLR9, P99L, Is Associated with Loss of CpG Oligonucleotide Responsiveness. <i>Journal of Biological Chemistry</i> , 2010, 285, 36486-36494.	2.2	28
202	An integrated expression phenotype mapping approach defines common variants in LEP, ALOX15 and CAPNS1 associated with induction of IL-6. <i>Human Molecular Genetics</i> , 2010, 19, 720-730.	2.9	25
203	Comment on "CRTAM Confers Late-Stage Activation of CD8+ T Cells to Regulate Retention within Lymph Node". <i>Journal of Immunology</i> , 2010, 184, 4052-4053.	0.6	1
204	Prime-Boost Immunization with Adenoviral and Modified Vaccinia Virus Ankara Vectors Enhances the Durability and Polyfunctionality of Protective Malaria CD8 + T-Cell Responses. <i>Infection and Immunity</i> , 2010, 78, 145-153.	2.7	185
205	Leprosy and the Adaptation of Human Toll-Like Receptor 1. <i>PLoS Pathogens</i> , 2010, 6, e1000979.	4.4	144
206	Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates. <i>Vaccine</i> , 2010, 29, 256-265.	3.1	72
207	Safety and Immunogenicity of a New Tuberculosis Vaccine, MVA85A, in Mycobacterium tuberculosis-infected Individuals. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 179, 724-733.	8.9	112
208	Consanguinity and susceptibility to infectious diseases in humans. <i>Biology Letters</i> , 2009, 5, 574-576.	2.5	64
209	Recombinant Viral Vaccines Expressing Merozoite Surface Protein-1 Induce Antibody- and T Cell-Mediated Multistage Protection against Malaria. <i>Cell Host and Microbe</i> , 2009, 5, 95-105.	15.1	65
210	Expression of tak1 and tram induces synergistic pro-inflammatory signalling and adjuvants DNA vaccines. <i>Vaccine</i> , 2009, 27, 5589-5598.	3.1	20
211	Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei. <i>European Journal of Immunology</i> , 2008, 38, 732-741.	3.2	95
212	Effective induction of high-titer antibodies by viral vector vaccines. <i>Nature Medicine</i> , 2008, 14, 819-821.	33.0	150
213	PTPRC (CD45) variation and disease association studied using single nucleotide polymorphism tagging. <i>Tissue Antigens</i> , 2008, 71, 458-463.	0.6	6
214	Helminth Infection and Eosinophilia and the Risk of Plasmodium falciparum Malaria in 1- to 6-Year-Old Children in a Malaria Endemic Area. <i>PLoS Neglected Tropical Diseases</i> , 2008, 2, e164.	3.0	36
215	CD209 Genetic Polymorphism and Tuberculosis Disease. <i>PLoS ONE</i> , 2008, 3, e1388.	2.3	103
216	Evidence of Blood Stage Efficacy with a Virosomal Malaria Vaccine in a Phase IIa Clinical Trial. <i>PLoS ONE</i> , 2008, 3, e1493.	2.3	103

#	ARTICLE	IF	CITATIONS
217	Recombination-Mediated Genetic Engineering of a Bacterial Artificial Chromosome Clone of Modified Vaccinia virus Ankara (MVA). PLoS ONE, 2008, 3, e1638.	2.3	91
218	Correlation of Memory T Cell Responses against TRAP with Protection from Clinical Malaria, and CD4+ CD25high T Cells with Susceptibility in Kenyans. PLoS ONE, 2008, 3, e2027.	2.3	85
219	Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa. PLoS ONE, 2008, 3, e2921.	2.3	46
220	Blood-stage Challenge for Malaria Vaccine Efficacy Trials: A Pilot Study with Discussion of Safety and Potential Value. American Journal of Tropical Medicine and Hygiene, 2008, 78, 878-883.	0.0	51
221	The Induction and Persistence of T Cell IFN- $\gamma$ Responses after Vaccination or Natural Exposure Is Suppressed by Plasmodium falciparum. Journal of Immunology, 2007, 179, 4193-4201.	0.6	96
222	Clearing asymptomatic parasitaemia increases the specificity of the definition of mild febrile malaria. Vaccine, 2007, 25, 8198-8202.	3.1	6
223	Functional polymorphisms in the FCN2 gene are not associated with invasive pneumococcal disease. Molecular Immunology, 2007, 44, 3267-3270.	2.2	41
224	Combination of Protein and Viral Vaccines Induces Potent Cellular and Humoral Immune Responses and Enhanced Protection from Murine Malaria Challenge. Infection and Immunity, 2007, 75, 5819-5826.	2.7	44
225	A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nature Genetics, 2007, 39, 523-528.	25.2	417
226	Extended Follow-Up Following a Phase 2b Randomized Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya. PLoS ONE, 2007, 2, e707.	2.3	58
227	Thick blood film examination for Plasmodium falciparum malaria has reduced sensitivity and underestimates parasite density. Malaria Journal, 2006, 5, .	2.6	110
228	A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS. Vaccine, 2006, 24, 2850-2859.	3.1	88
229	PTPN22 and invasive bacterial disease. Nature Genetics, 2006, 38, 499-500.	25.2	55
230	Aspects of Genetic Susceptibility to Human Infectious Diseases. Annual Review of Genetics, 2006, 40, 469-486.	7.2	249
231	Dimorphic Plasmodium falciparum merozoite surface protein-1 epitopes turn off memory T cells and interfere with T cell priming. European Journal of Immunology, 2006, 36, 1168-1178.	3.2	23
232	Alternating vector immunizations encoding pre-erythrocytic malaria antigens enhance memory responses in a malaria endemic area. European Journal of Immunology, 2006, 36, 2264-2272.	3.2	24
233	Class II cytokine receptor gene cluster is a major locus for hepatitis B persistence. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 9148-9153.	7.5	102
234	A Phase 2b Randomised Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya. PLOS Clinical Trials, 2006, 1, e29.	2.9	126

#	ARTICLE	IF	CITATIONS
235	Safety, Immunogenicity, and Efficacy of Prime-Boost Immunization with Recombinant Poxvirus FP9 and Modified Vaccinia Virus Ankara Encoding the Full-Length Plasmodium falciparum Circumsporozoite Protein. <i>Infection and Immunity</i> , 2006, 74, 2706-2716.	2.7	62
236	A Polymorphism That Reduces RANTES Expression Is Associated with Protection from Death in HIV-1 Seropositive Ugandans with Advanced Disease. <i>Journal of Infectious Diseases</i> , 2006, 194, 666-669.	3.8	27
237	Early Gamma Interferon and Interleukin-2 Responses to Vaccination Predict the Late Resting Memory in Malaria-Naïve and Malaria-Exposed Individuals. <i>Infection and Immunity</i> , 2006, 74, 6331-6338.	2.7	22
238	Variants in the SP110 gene are associated with genetic susceptibility to tuberculosis in West Africa. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 10364-10368.	7.5	108
239	Variation in MICA and MICB genes and enhanced susceptibility to paucibacillary leprosy in South India. <i>Human Molecular Genetics</i> , 2006, 15, 2880-2887.	2.9	45
240	Prime-boost immunisation strategies for tuberculosis. <i>Microbes and Infection</i> , 2005, 7, 962-967.	2.4	106
241	Direct processing and presentation of antigen from malaria sporozoites by professional antigen-presenting cells in the induction of CD8 <sup>+</sup> T cell responses. <i>Immunology and Cell Biology</i> , 2005, 83, 307-312.	2.6	63
242	Molecular analysis of HLA class II associations with hepatitis B virus clearance and vaccine nonresponsiveness. <i>Hepatology</i> , 2005, 41, 1383-1390.	10.1	128
243	Calculation of Liver-to-Blood Inocula, Parasite Growth Rates, and Preerythrocytic Vaccine Efficacy, from Serial Quantitative Polymerase Chain Reaction Studies of Volunteers Challenged with Malaria Sporozoites. <i>Journal of Infectious Diseases</i> , 2005, 191, 619-626.	3.8	156
244	Invariant $\gamma\delta$ 14 Chain NKT Cells Promote Plasmodium berghei Circumsporozoite Protein-Specific Gamma Interferon- and Tumor Necrosis Factor Alpha-Producing CD8 <sup>+</sup> T Cells in the Liver after Poxvirus Vaccination of Mice. <i>Infection and Immunity</i> , 2005, 73, 849-858.	2.7	21
245	Inverse Associations of Human Leukocyte Antigen and Malaria Parasite Types in Two West African Populations. <i>Infection and Immunity</i> , 2005, 73, 953-955.	2.7	11
246	Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 4836-4841.	7.5	231
247	Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720. <i>Vaccine</i> , 2005, 23, 857-864.	3.1	73
248	Pre-erythrocytic malaria vaccines: towards greater efficacy. <i>Nature Reviews Immunology</i> , 2005, 6, 21-32.	53.8	129
249	QUANTITATIVE REAL-TIME POLYMERASE CHAIN REACTION FOR MALARIA DIAGNOSIS AND ITS USE IN MALARIA VACCINE CLINICAL TRIALS. <i>American Journal of Tropical Medicine and Hygiene</i> , 2005, 73, 191-198.	0.0	99
250	A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 290-295.	7.5	59
251	Vitamin D Receptor Polymorphisms and Susceptibility to Tuberculosis in West Africa: A Case-Control and Family Study. <i>Journal of Infectious Diseases</i> , 2004, 190, 1631-1641.	3.8	137
252	Cellular immune responses induced in cattle by heterologous prime-boost vaccination using recombinant viruses and bacille Calmette-Guerin. <i>Immunology</i> , 2004, 112, 461-470.	4.7	112

#	ARTICLE	IF	CITATIONS
253	Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. <i>Nature Medicine</i> , 2004, 10, 1240-1244.	33.0	547
254	Splenic dendritic cell subsets prime and boost CD8 T cells and are involved in the generation of effector CD8 T cells. <i>Cellular Immunology</i> , 2004, 228, 15-19.	2.5	19
255	CD45 variant alleles: possibly increased frequency of a novel exon 4 CD45 polymorphism in HIV seropositive Ugandans. <i>Immunogenetics</i> , 2004, 56, 107-110.	2.8	9
256	Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction. <i>Vaccine</i> , 2004, 22, 4326-4331.	3.1	18
257	Malaria vaccine developments. <i>Lancet, The</i> , 2004, 363, 150-156.	62.3	165
258	LARGE-SCALE CANDIDATE GENE STUDY OF LEPROSY SUSCEPTIBILITY IN THE KARONGA DISTRICT OF NORTHERN MALAWI. <i>American Journal of Tropical Medicine and Hygiene</i> , 2004, 71, 330-340.	0.0	72
259	LARGE-SCALE CANDIDATE GENE STUDY OF TUBERCULOSIS SUSCEPTIBILITY IN THE KARONGA DISTRICT OF NORTHERN MALAWI. <i>American Journal of Tropical Medicine and Hygiene</i> , 2004, 71, 341-349.	0.0	103
260	Interleukin-10 promoter polymorphisms and the outcome of hepatitis C virus infection. <i>Immunogenetics</i> , 2003, 55, 362-369.	2.8	152
261	Variants of the CD40 ligand gene are not associated with increased susceptibility to tuberculosis in West Africa. <i>Immunogenetics</i> , 2003, 55, 502-507.	2.8	16
262	Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection. <i>Hepatology</i> , 2003, 38, 1468-1476.	10.1	121
263	Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. <i>Nature Medicine</i> , 2003, 9, 729-735.	33.0	541
264	Genetic susceptibility to infectious disease. <i>Trends in Microbiology</i> , 2003, 11, 445-448.	8.2	134
265	Heterologous Priming-Boosting Immunization of Cattle with <i>Mycobacterium tuberculosis</i> 85A Induces Antigen-Specific T-Cell Responses. <i>Infection and Immunity</i> , 2003, 71, 6906-6914.	2.7	26
266	Interleukin-1 gene cluster polymorphisms and susceptibility to clinical malaria in a Gambian case-control study. <i>European Journal of Human Genetics</i> , 2003, 12, 132-138.	3.0	63
267	EX VIVO INTERFERON-GAMMA IMMUNE RESPONSE TO THROMBOSPONDIN-RELATED ADHESIVE PROTEIN IN COASTAL KENYANS: LONGEVITY AND RISK OF PLASMODIUM FALCIPARUM INFECTION. <i>American Journal of Tropical Medicine and Hygiene</i> , 2003, 68, 421-430.	0.0	35
268	ASSOCIATION OF Fcγ3 RECEPTOR IIa (CD32) POLYMORPHISM WITH SEVERE MALARIA IN WEST AFRICA. <i>American Journal of Tropical Medicine and Hygiene</i> , 2003, 69, 565-568.	0.0	85
269	Induction of T Helper Type 1 and 2 Responses to 19-Kilodalton Merozoite Surface Protein 1 in Vaccinated Healthy Volunteers and Adults Naturally Exposed to Malaria. <i>Infection and Immunity</i> , 2002, 70, 1417-1421.	2.7	37
270	A Region of Chromosome 20 Is Linked to Leprosy Susceptibility in a South Indian Population. <i>Journal of Infectious Diseases</i> , 2002, 186, 1190-1193.	3.8	65

#	ARTICLE	IF	CITATIONS
271	Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. <i>Vaccine</i> , 2002, 20, 1039-1045.	3.1	158
272	Chemokine-receptor genes and AIDS risk. <i>Nature</i> , 2002, 417, 140-140.	37.9	22
273	Transmission of hepatitis B virus infection in Gambian families revealed by phylogenetic analysis. <i>Journal of Hepatology</i> , 2001, 35, 99-104.	4.2	98
274	A prime-boost immunisation regimen using DNA followed by recombinant modified vaccinia virus Ankara induces strong cellular immune responses against the Plasmodium falciparum TRAP antigen in chimpanzees. <i>Vaccine</i> , 2001, 19, 4595-4602.	3.1	60
275	THE GENOMICS AND GENETICS OF HUMAN INFECTIOUS DISEASES SUSCEPTIBILITY. <i>Annual Review of Genomics and Human Genetics</i> , 2001, 2, 373-400.	6.7	237
276	Immunogenetics and genomics. <i>Lancet</i> , The, 2001, 357, 2037-2041.	62.3	64
277	Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. <i>Lancet</i> , The, 2001, 358, 1927-1934.	62.3	500
278	Enhanced Immunogenicity of CD4+ T-Cell Responses and Protective Efficacy of a DNA-Modified Vaccinia Virus Ankara Prime-Boost Vaccination Regimen for Murine Tuberculosis. <i>Infection and Immunity</i> , 2001, 69, 681-686.	2.7	220
279	Induction of CD8 + T lymphocyte responses to a secreted antigen of Mycobacterium tuberculosis by an attenuated vaccinia virus. <i>Immunology and Cell Biology</i> , 2001, 79, 569-575.	2.6	21
280	Prevalence of HBV core promoter/precure/core mutations in Gambian chronic carriers. <i>Journal of Medical Virology</i> , 2001, 65, 664-670.	3.7	24
281	A major susceptibility locus for leprosy in India maps to chromosome 10p13. <i>Nature Genetics</i> , 2001, 27, 439-441.	25.2	173
282	Genetics of susceptibility to human infectious disease. <i>Nature Reviews Genetics</i> , 2001, 2, 967-977.	47.0	457
283	Strong HLA Class II Restricted T Cell Responses in Dengue Hemorrhagic Fever: A Double-Edged Sword?. <i>Journal of Infectious Diseases</i> , 2001, 184, 1369-1373.	3.8	171
284	Genetic Regulation of Acquired Immune Responses to Antigens of Mycobacterium tuberculosis: a Study of Twins in West Africa. <i>Infection and Immunity</i> , 2001, 69, 3989-3994.	2.7	95
285	Association of NRAM1 polymorphism with leprosy type but not susceptibility to leprosy per se in west Africans.. <i>American Journal of Tropical Medicine and Hygiene</i> , 2001, 65, 733-735.	0.0	66
286	High frequencies of circulating IFN- $\gamma$ -secreting CD8 cytotoxic T cells specific for a novel MHC class I-restricted Mycobacterium tuberculosis epitope in M. tuberculosis-infected subjects without disease. <i>European Journal of Immunology</i> , 2000, 30, 2713-2721.	3.2	94
287	Improved method for distinguishing the human source of mosquito blood meals between close family members. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2000, 94, 572-574.	1.4	25
288	The immunology of malaria infection. <i>Current Opinion in Immunology</i> , 2000, 12, 437-441.	5.2	115

#	ARTICLE	IF	CITATIONS
289	In vivo antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitope. <i>Nature Medicine</i> , 2000, 6, 337-342.	33.0	550
290	Vaccines against intracellular infections requiring cellular immunity. <i>Nature</i> , 2000, 406, 793-798.	37.9	362
291	Cytotoxic T-Lymphocyte Epitopes for HLA-B53 and Other HLA Types in the Malaria Vaccine Candidate Liver-Stage Antigen 3. <i>Infection and Immunity</i> , 2000, 68, 227-232.	2.7	49
292	Secretor Polymorphism and Human Immunodeficiency Virus Infection in Senegalese Women. <i>Journal of Infectious Diseases</i> , 2000, 181, 737-739.	3.8	49
293	Severe Malarial Anemia and Cerebral Malaria Are Associated with Different Tumor Necrosis Factor Promoter Alleles. <i>Journal of Infectious Diseases</i> , 1999, 179, 287-290.	3.8	235
294	Induction of CD8+ T cells using heterologous prime-boost immunisation strategies. <i>Immunological Reviews</i> , 1999, 170, 29-38.	6.5	181
295	Altered peptide ligands narrow the repertoire of cellular immune responses by interfering with T-cell priming. <i>Nature Medicine</i> , 1999, 5, 565-571.	33.0	98
296	Broadly distributed T cell reactivity, with no immunodominant loci, to the pre-erythrocytic antigen thrombospondin-related adhesive protein of <i>Plasmodium falciparum</i> in West Africans. <i>European Journal of Immunology</i> , 1999, 29, 1943-1954.	3.2	47
297	Potent Induction of Focused Th1-type Cellular and Humoral Immune Responses by RTS,S/SBAS2, a Recombinant <i>Plasmodium falciparum</i> Malaria Vaccine. <i>Journal of Infectious Diseases</i> , 1999, 180, 1656-1664.	3.8	154
298	An Empirical Exploration of the $(\frac{1}{4})^2$ Genetic Distance for 213 Human Microsatellite Markers. <i>American Journal of Human Genetics</i> , 1999, 65, 1125-1133.	6.5	30
299	Effective induction of HIV-specific CTL by multi-epitope using gene gun in a combined vaccination regime. <i>Vaccine</i> , 1999, 17, 589-596.	3.1	97
300	Gene gun intradermal DNA immunization followed by boosting with modified vaccinia virus Ankara: enhanced CD8+ T cell immunogenicity and protective efficacy in the influenza and malaria models. <i>Vaccine</i> , 1999, 18, 623-632.	3.1	96
301	Genetics and genomics of infectious disease susceptibility. <i>British Medical Bulletin</i> , 1999, 55, 401-413.	4.0	76
302	The Immunogenetics of Resistance to Malaria. <i>Proceedings of the Association of American Physicians</i> , 1999, 111, 272-277.	3.0	56
303	Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. <i>Nature Medicine</i> , 1998, 4, 397-402.	33.0	645
304	Protection from <i>Plasmodium berghei</i> infection by priming and boosting T cells to a single class I-restricted epitope with recombinant carriers suitable for human use. <i>European Journal of Immunology</i> , 1998, 28, 4345-4355.	3.2	83
305	Glucose-6-phosphate dehydrogenase deficiency and malaria. <i>Journal of Molecular Medicine</i> , 1998, 76, 581-588.	3.7	222
306	Absence of an association between intercellular adhesion molecule 1, complement receptor 1 and interleukin 1 receptor antagonist gene polymorphisms and severe malaria in a West African population. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 1998, 92, 312-316.	1.4	85

#	ARTICLE	IF	CITATIONS
307	DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: immunogenicity in mice. <i>Vaccine</i> , 1998, 16, 426-435.	3.1	126
308	THE IMMUNOGENETICS OF HUMAN INFECTIOUS DISEASES. <i>Annual Review of Immunology</i> , 1998, 16, 593-617.	29.5	527
309	Heterogeneity of Microsatellite Mutations Within and Between Loci, and Implications for Human Demographic Histories. <i>Genetics</i> , 1998, 148, 1269-1284.	4.2	155
310	Rapid Effector Function in CD8+ Memory T Cells. <i>Journal of Experimental Medicine</i> , 1997, 186, 859-865.	9.2	633
311	Genetic analysis of host-parasite coevolution in human malaria. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 1997, 352, 1317-1325.	3.7	72
312	A protein particle vaccine containing multiple malaria epitopes. <i>Nature Biotechnology</i> , 1997, 15, 1280-1284.	29.8	154
313	Heterozygote advantage for HLA class-II type in hepatitis B virus infection. <i>Nature Genetics</i> , 1997, 17, 11-12.	25.2	297
314	Optimization of a peptide-based protocol employing IL-7 for in vitro restimulation of human cytotoxic T lymphocyte precursors. <i>Journal of Immunological Methods</i> , 1997, 210, 65-77.	1.4	79
315	A distinctive peptide binding motif for HLA-DRB1 * 0407, an HLA-DR4 subtype not associated with rheumatoid arthritis. <i>Immunogenetics</i> , 1997, 45, 229-232.	2.8	16
316	T-cell receptor variable alpha (TCRAV) polymorphisms in European, Chinese, South American, AfroCaribbean, and Gambian populations. <i>Immunogenetics</i> , 1997, 47, 124-130.	2.8	5
317	Genetic susceptibility to multifactorial diseases. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 1997, 91, 369-371.	1.4	1
318	Genetic linkage of mild malaria to the major histocompatibility complex in Gambian children: study of affected sibling pairs: Table 1. <i>BMJ: British Medical Journal</i> , 1997, 315, 96-97.	0.1	67
319	Reverse immunogenetics: from HLA-disease associations to vaccine candidates. <i>Trends in Molecular Medicine</i> , 1996, 2, 38-45.	2.5	63
320	Genetics of infectious disease resistance. <i>Current Opinion in Genetics and Development</i> , 1996, 6, 348-353.	3.2	65
321	Cytotoxic T lymphocytes to Plasmodium falciparum epitopes in an area of intense and perennial transmission in Tanzania. <i>European Journal of Immunology</i> , 1996, 26, 773-779.	3.2	54
322	Comparison of numerous delivery systems for the induction of cytotoxic T lymphocytes by immunization. <i>European Journal of Immunology</i> , 1996, 26, 1951-1959.	3.2	89
323	Induction of peptide-specific primary cytotoxic T lymphocyte responses from human peripheral blood. <i>European Journal of Immunology</i> , 1995, 25, 1783-1787.	3.2	44
324	Association of hepatitis B surface antigen carriage with severe malaria in Gambian children. <i>Nature Medicine</i> , 1995, 1, 374-375.	33.0	63

#	ARTICLE	IF	CITATIONS
325	Variation in the TNF- $\alpha$ promoter region associated with susceptibility to cerebral malaria. <i>Nature</i> , 1994, 371, 508-511.	37.9	1,186
326	HLA, malaria and dominant protective associations. <i>Parasitology Today</i> , 1992, 8, 57.	0.0	5
327	Molecular analysis of the association of HLA-B53 and resistance to severe malaria. <i>Nature</i> , 1992, 360, 434-439.	37.9	648
328	Common West African HLA antigens are associated with protection from severe malaria. <i>Nature</i> , 1991, 352, 595-600.	37.9	1,527
329	Mapping immune variation and var gene switching in naive hosts infected with <i>Plasmodium falciparum</i> . <i>ELife</i> , 0, 10, .	1.6	31
330	BIRC6 modifies risk of invasive bacterial infection in Kenyan children. <i>ELife</i> , 0, 11, .	1.6	8